Like most payers, Medicaid programs struggle with the cost of drugs. A report from Magellan Health gives some trends and data on prescription medication use in the Medicaid sector. (Magellan Report) The report covers 2018 and is based on Magellan’s customers’ experience. As always when looking at medication spending trends, it is important to try to disentangle the effects of utilization and prices, and to focus on net spending after rebates and discounts. The federal government mandates very significant discounts for the Medicaid programs and states may have their own additional rebate arrangements. It is useful to look at the last three years. In 2016, total net trend was a 1.9% increase, but while traditional drug, branded and generic, spending declined, that on specialty drugs rose 20.5%. In 2017, the total rise was actually a decline of 4.4%, with traditional spending going down 9.7% while specialty rose 4.6%. And in 2018, the total increase in spending was .8%, traditional declined 2.6% and specialty rose 6.1%. The gross or pre-discount cost in 2017 was $108.88 per claim while the net or after discount cost was $45.66, which shows the size of Medicaid rebates. In 2018 the numbers were $113.32 gross cost per claim and $46.03 net. Out of the .8% rise in net spending in 2018, traditional drug price contributed a seventy-one cent decline, while traditional utilization was responsible for a 5.2% decline, which is a little surprising. On the specialty side, there was a $77 increase in prices but a 5.5% decline in utilization. To give you a better sense of just how impactful specialty drugs are, they represent only 1.5% of all claims, but account for 43% of net spending. Magellan is projecting that net Medicaid spending will continue to increase more rapidly in the next three years, but still be very modest at around 2% a year, all driven by specialty drug pricing. The top therapeutic categories for Medicaid spending are HIV, anti-psychotics and hemophilia. Some of the approaches, in addition to the usual discounts and rebates, that states are trying in their efforts to control spending include outcomes-based contracting and subscription approaches.
Medicaid Medication Costs
No Comments
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
Research
MedPAC 2019 Report to Congress
June 18, 2019
Headlines
Tags
Access
ACO
Care Management
Chronic Disease
Comparative Effectiveness
Consumer Directed Health
Consumers
Devices
Disease Management
Drugs
EHRs
Elder Care
End-of-Life Care
FDA
Financings
Genomics
Government
Health Care Costs
Health Care Quality
Health Care Reform
Health Insurance
Health Insurance Exchange
HIT
HomeCare
Hospital
Hospital Readmissions
Legislation
M&A
Malpractice
Meaningful Use
Medicaid
Medical Care
Medicare
Medicare Advantage
Mobile
Pay For Performance
Pharmaceutical
Physicians
Providers
Regulation
Repealing Reform
Telehealth
Telemedicine
Wellness and Prevention
Workplace
Related Posts
Commentary
April 25, 2024
Uh-oh, the Economic Crap Hits the Fan
The economy is slowing and inflation accelerating while productivity declines. What a great combination.
Commentary
April 25, 2024
Another of Your Regular US Debt Sales Updates
The five-year US Treasury note runs into resistance in a weaker auction than that for…
Commentary
April 24, 2024
More Real Climate Science
A new set of studies undercuts the entire CO2 will cause further warming hypothesis.